Clinical Trial Update: Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda [Phase 2, Phase 3]

View source ↗

Summary

A late-stage trial of the eflornithine plus nifurtimox combination for human African trypanosomiasis in West Nile, Uganda has been terminated (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human African Trypanosomiasis

Drugs mentioned

• Eflornithine (eflornithine)
• Nifurtimox (Nifurtimox)

Snippet

Sponsor: Epicentre | Conditions: Trypanosomiasis, African | Phase 2, Phase 3 | Status: TERMINATED